English Silicon Intelligence (03696.HK) and Hengtai Biotech have jointly achieved the first clinical milestone with ISM8969, completing the first human dosing in Phase I study.

The financial news app, Smart Finance APP, reported that British Silicon Intelligence (03696.HK) announced that the company's joint development with Shenzhen Hengtai Biotechnology Co., Ltd. (Hengtai Biotechnology) of ISM8969 has reached the first clinical milestone, completing the first human dose in Phase I research.